Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774696 | 0.79 | IKBKB (0.41) | MAPKAPK2HPGDALDH1A1KDM4EGAA | |
| SCHEMBL5778419 | 0.79 | MAPKAPK2 (0.40) | MAPKAPK2HPGDKMT2ATP53HTT | |
| SCHEMBL5772540 | 0.78 | MAPKAPK2 (0.39) | MAPKAPK2HPGDKMT2ATP53HTT | |
| SCHEMBL5776551 | 0.78 | IKBKB (0.40) | MAPKAPK2HPGDKMT2AALDH1A1KDM4E | |
| SCHEMBL6948732 | 0.69 | ALDH1A1 (0.36) | MAPKAPK2HPGDTP53HTTALDH1A1 | |
| SCHEMBL15647191 | 0.67 | ALDH1A1 (0.46) | MAPKAPK2HPGDKMT2AALDH1A1KDM4E | |
| SCHEMBL2798485 | 0.66 | TAAR1 (0.43) | MAPKAPK2HPGDKMT2ATP53HTT | |
| SCHEMBL27784460 | 0.65 | PTGES2 (0.32) | CFTRMAPKAPK2 | |
| Ammonia Solution, Strong SCHEMBL28458763 | 0.64 | TAAR1 (0.42) | MAPKAPK2HPGDKMT2ATP53HTT | |
| SCHEMBL19652158 | 0.64 | GRM5 (0.38) | CFTRHPGDTP53ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | CFTR 890/4885MAPKAPK2 4313/4885HPGD 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.